We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+42.47%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$354M
AUM Growth
+$83.8M
Cap. Flow
+$17.9M
Cap. Flow %
5.04%
Top 10 Hldgs %
61.1%
Holding
35
New
–
Increased
14
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$8.63M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$8.47M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.11M
4
EVH icon
Evolent Health
EVH
+$5.67M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$5.26M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$7.85M
2
GILD icon
Gilead Sciences
GILD
+$5.31M
3
AMRS
Amyris Inc.
AMRS
+$1.59M
4
TSRO
TESARO, Inc.
TSRO
+$1.18M
5
SAGE
Sage Therapeutics
SAGE
+$1.18M

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVID icon
26
Ovid Therapeutics
OVID
$435M
$1.78M 0.5%
207,500
-14,200
-6% -$118K
CRIS icon
27
Curis
CRIS
$10M
– –
-43
Closed -$161K
GILD icon
28
CALL
Gilead Sciences
GILD
$163B
– –
-60,000
Closed -$4.25M
GILD icon
29
Gilead Sciences
GILD
$163B
– –
-75,000
Closed -$5.31M
MYGN icon
30
CALL
Myriad Genetics
MYGN
$285M
– –
-100,000
Closed -$2.58M
PACB icon
31
Pacific Biosciences
PACB
$441M
– –
-300,000
Closed -$1.07M
XBI icon
32
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
– –
-150,000
Closed -$11.6M
MDRX
33
CALL
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-150,000
Closed -$1.91M
AMRS
34
DELISTED
Amyris Inc.
AMRS
– –
-500,000
Closed -$1.59M
EPZM
35
DELISTED
Epizyme, Inc
EPZM
– –
-520,000
Closed -$7.85M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Casdin Capital held 35 positions worth $354M, up 31% from $270M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Casdin Capital deployed $17.9M of net new capital in Q3 2017, adding to 14 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was TESARO, Inc., an estimated $1.18M trimmed.

  • Casdin Capital added most to bluebird bio in Q3 2017, an estimated $8.63M increase.
  • Casdin Capital's biggest Q3 2017 reduction was TESARO, Inc., cutting an estimated $1.18M.
  • Casdin Capital fully exited Epizyme, Inc in Q3 2017, selling an estimated $7.85M.
  • Casdin Capital's ten largest holdings make up 61% of its $354M portfolio in Q3 2017.
  • Casdin Capital opened 0 new positions and closed 9 in Q3 2017.
  • Casdin Capital's portfolio value rose 31% quarter-over-quarter to $354M.

Based on Casdin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.